Trial Profile
A Phase 2 Randomized, Double-blind, Placebo-controlled Trial and Open Label Extension to Evaluate the Safety and Efficacy of Deupirfenidone (LYT-100) in Post-acute COVID-19 Respiratory Disease
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 19 Feb 2024
Price :
$35
*
At a glance
- Drugs Deupirfenidone (Primary)
- Indications COVID-19 pneumonia; Post acute COVID 19 syndrome
- Focus Adverse reactions; Therapeutic Use
- Sponsors PureTech Health
- 12 Feb 2024 Status changed from completed to discontinued.
- 24 May 2023 Primary endpoint (Change in distance walked on the six-minute walk test (6MWT)) has not been met, as per results presented at the 119th International Conference of the American Thoracic Society.
- 24 May 2023 Results assessing the safety and efficacy of LYT-100 in presenting with respiratory complications patients with respiratory complications, presented at the 119th International Conference of the American Thoracic Society.